AVROBIO, Inc. (NASDAQ:AVRO - Free Report) shares are scheduled to reverse split before the market opens on Thursday, June 20th. The 1-12 reverse split was announced on Thursday, June 20th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, June 20th.
AVROBIO Trading Down 2.7 %
Shares of AVRO traded down $0.04 during mid-day trading on Tuesday, hitting $1.42. 240,658 shares of the company traded hands, compared to its average volume of 270,364. The stock has a market capitalization of $63.74 million, a price-to-earnings ratio of 2.12 and a beta of 1.23. The business has a 50-day moving average of $1.34 and a 200 day moving average of $1.33. AVROBIO has a one year low of $0.88 and a one year high of $1.65.
AVROBIO (NASDAQ:AVRO - Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. As a group, analysts anticipate that AVROBIO will post -0.48 earnings per share for the current year.
Insider Activity
In other AVROBIO news, major shareholder Braden Michael Leonard purchased 469,753 shares of the company's stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average cost of $1.25 per share, with a total value of $587,191.25. Following the completion of the purchase, the insider now directly owns 4,471,380 shares in the company, valued at approximately $5,589,225. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 9.20% of the company's stock.
Institutional Trading of AVROBIO
Institutional investors and hedge funds have recently modified their holdings of the stock. Newtyn Management LLC acquired a new stake in shares of AVROBIO in the 3rd quarter valued at about $3,080,000. Terrapin Asset Management LLC bought a new stake in AVROBIO in the 3rd quarter valued at approximately $861,000. Affinity Asset Advisors LLC bought a new stake in AVROBIO in the 3rd quarter valued at approximately $770,000. Aldebaran Capital LLC acquired a new position in AVROBIO during the 3rd quarter worth approximately $724,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of AVROBIO during the 4th quarter worth approximately $480,000. 62.63% of the stock is owned by institutional investors.
AVROBIO Company Profile
(
Get Free Report)
AVROBIO, Inc, a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.
See Also
Before you consider AVROBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AVROBIO wasn't on the list.
While AVROBIO currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
